What Is Cortexin?
Cortexin is a polypeptide neuropeptide complex derived from porcine (pig) cerebral cortex tissue, manufactured by Geropharm in Russia. Like Cerebrolysin, it contains a broad spectrum of low-molecular-weight neuropeptides including BDNF, NGF, CNTF, and GDNF, along with amino acids and microelements. It is the most widely used nootropic drug in Russia and Eastern Europe, with over 30 years of clinical use and multiple published clinical trials in stroke, TBI, cognitive decline, and childhood neurodevelopmental disorders. In research communities, it is frequently cited as a Cerebrolysin alternative — offering similar neuroprotective and neurorestorative mechanisms with the advantage of IM-only administration (no IV requirement).
Mechanism: Polypeptide Neuroprotection
Cortexin provides exogenous neuropeptides that cross the blood-brain barrier, modulate neurotransmitter levels, promote neuroplasticity, reduce oxidative stress in neuronal tissue, and regulate apoptosis. The mechanism is similar to Cerebrolysin but the specific peptide composition differs — Cortexin is derived from cerebral cortex while Cerebrolysin uses whole brain tissue. The 10 mg IM daily protocol used in research mirrors approved clinical protocols in Russia and Eastern Europe.
Comparison to Cerebrolysin
Cortexin and Cerebrolysin are the two most-studied polypeptide neuropeptide complexes. Key differences: Cortexin is IM-only (simpler administration), Cerebrolysin is IM or IV (IV enables higher dose delivery). Both are 10-day cycle compounds. Cerebrolysin has more published Western clinical trial data; Cortexin has a larger Eastern European clinical evidence base and is the more widely prescribed of the two in Russia. For practical research purposes, either can serve as a neurorestorative cycle compound — the choice often comes down to sourcing and preference for IM vs. IV administration.
Quick Reference
Member reference tables summarize the compound's research parameters.
Research Indications
Neurorestorative and neuroprotective research; post-stroke cognitive recovery; TBI recovery; age-related cognitive decline; neurodevelopmental disorders (extensive pediatric literature in Eastern Europe); general neuroplasticity enhancement in cognitive optimization protocols.
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below), not a personal dosing recommendation.
This member section describes parameters reported in the research literature.
Peptide Interactions
This member section summarizes reported compound interactions and evidence limitations.
Reported Research Time Points
This member section summarizes reported research time points.
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
This member section discusses research safety considerations and uncertainties.
Quality Indicators
Research Citations
- Skvortsova et al. (2006) — Cortexin in stroke rehabilitation: randomized controlled trial
Zhurnal Nevrologii i Psikhiatrii - Romanenko et al. (2007) — Cortexin neuroprotection in acute ischemic stroke: clinical outcomes study
Neuroscience and Behavioral Physiology - Voznesenskaya et al. (2018) — Cortexin efficacy in mild cognitive impairment: a multicenter Russian trial
Zhurnal Nevrologii i Psikhiatrii - Khavinson V.Kh. et al. — Peptide bioregulators of brain function: 30-year overview of Cortexin clinical use in Russia
Bulletin of Experimental Biology and Medicine